Recent Collaborations in Biotech

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts provides insights on recent collaborative advancements across the global biotech landscape. The TOE also provides additional analysis of CRSIPR-based clinical trials.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The H

Table of Contents

Recent Collaborations in BiotechPartnerships Leading the Biotech LandscapeAgilent Technologies Collaborates with University of Southern California for Enabling Convergence of Bioscience ResearchSanofi to Acquire Biotechnology Firm Ablynx, a Developer of the Unique Nanobody PlatformShire Plc and AB Biosciences Enter into a Licensing Agreement for Working on the PRIM ProgramAdverum Biotechnologies Intends to Partner with Editas MedicineClinical Trial Analysis and Industry InteractionsClinical Trial Analysis for CRISPR Clinical Trial Analysis for CRISPR (continued)Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.